Amgen Halts Clinical Trials of Gastric Cancer Drug after Deaths

Drug Industry Daily
A A
Amgen pulled the plug on its experimental stomach cancer drug rilotumumab after data from two late-stage clinical trials raised serious safety concerns, marking the company’s second failed cancer drug this month.

To View This Article:

Login

Subscribe To Drug Industry Daily